Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03502330
Title APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Yale University


lung non-small cell carcinoma

renal cell carcinoma


APX005M + Cabiralizumab + Nivolumab

APX005M + Cabiralizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.